

Special Issue

Liquid Biopsy in Cancer

Message from the Guest Editors

Precision medicine is becoming the new paradigm in healthcare as it enables treatment optimization, a potential reduction in side effects, and better resources allocation. Liquid biopsy is the cornerstone of this revolution since it provides real-time prognostic and predictive information for advanced cancer patients without the analytical and procedural drawbacks of tissue biopsy. Several technologies are comprised under the umbrella term of “liquid biopsy”, each with its strengths and peculiarities. In particular, circulating tumor DNA (ctDNA) together with circulating tumor cells (CTCs) and microvesicles are gaining momentum as promising markers for early disease characterization and longitudinal monitoring for resistance detection. This Special Issue is aimed at summarizing both analytical developments and clinical evidence regarding the application of liquid biopsy across the major cancer types, with a special focus on its clinical utility and how its deployment will ultimately lead to the growing personalization of cancer care.

Guest Editors

Prof. Dr. Fabio Puglisi

1. Department of Medical Oncology, IRCCS, CRO di Aviano, National Cancer Institute, Aviano, Italy
2. Department of Medicine, University of Udine, 33100 Udine, Italy

Dr. Lorenzo Gerratana

1. Department of Medical Oncology, IRCCS, CRO di Aviano, National Cancer Institute, Aviano, Italy
2. Department of Medicine, University of Udine, 33100 Udine, Italy

Deadline for manuscript submissions

closed (31 December 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/33347

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)